Diagonal Bio AB (publ) (DIABIO.ST)
SEK 0.02
(4.18%)
SEK 0.02
(4.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.13 Million SEK | -662.12% |
| 2022 | 2.05 Million SEK | 2516.47% |
| 2021 | -85 Thousand SEK | 86.01% |
| 2020 | -607.55 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -70 Thousand SEK | -114.0% |
| 2024 Q3 | -314 Thousand SEK | -348.57% |
| 2024 Q1 | 500 Thousand SEK | 120.37% |
| 2023 Q2 | 1.81 Million SEK | -11.99% |
| 2023 FY | -11.54 Million SEK | -662.12% |
| 2023 Q4 | -2.45 Million SEK | -256.21% |
| 2023 Q1 | 2.06 Million SEK | 90.39% |
| 2023 Q3 | 1.57 Million SEK | -13.35% |
| 2022 FY | 2.05 Million SEK | 2516.47% |
| 2022 Q4 | 1.08 Million SEK | -50.55% |
| 2022 Q3 | 2.18 Million SEK | 339.36% |
| 2022 Q2 | 498 Thousand SEK | 19.14% |
| 2022 Q1 | 418 Thousand SEK | 664.86% |
| 2021 Q2 | -6000.00 SEK | 0.0% |
| 2021 FY | -85 Thousand SEK | 86.01% |
| 2021 Q3 | -6000.00 SEK | 0.0% |
| 2021 Q4 | -74 Thousand SEK | -1133.33% |
| 2021 Q1 | - SEK | 100.0% |
| 2020 Q4 | -99.33 Thousand SEK | -257.67% |
| 2020 Q2 | -33 Thousand SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | -607.55 Thousand SEK | 0.0% |
| 2020 Q3 | 63 Thousand SEK | 290.91% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 101.95% |
| Ziccum AB (publ) | -23.28 Million SEK | 113.454% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 99.095% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 92.502% |
| Mendus AB (publ) | 28.48 Million SEK | 89.002% |
| Genovis AB (publ.) | 54 Million SEK | 94.198% |
| Intervacc AB (publ) | -13.79 Million SEK | 122.713% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -44.311% |
| Active Biotech AB (publ) | -1.67 Million SEK | 287.045% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 68.554% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 88.319% |
| Aptahem AB (publ) | 2.63 Million SEK | -19.096% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 191.581% |
| Kancera AB (publ) | -1.96 Million SEK | 259.44% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -3968.831% |
| Fluicell AB (publ) | 1.73 Million SEK | -80.265% |
| Saniona AB (publ) | 11.78 Million SEK | 73.406% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 161.227% |
| Biovica International AB (publ) | 6.87 Million SEK | 54.442% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 113.456% |
| AcouSort AB (publ) | 8.38 Million SEK | 62.653% |
| Xintela AB (publ) | 78 Thousand SEK | -3916.667% |
| Abliva AB (publ) | -35.66 Million SEK | 108.785% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 102.133% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -11.614% |
| OncoZenge AB (publ) | 3000.00 SEK | -104333.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 262.332% |
| 2cureX AB (publ) | -37.48 Million SEK | 108.358% |
| CombiGene AB (publ) | -21.29 Million SEK | 114.715% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 840.662% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.723% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.802% |
| Corline Biomedical AB | 28.38 Million SEK | 88.961% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 102.553% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 109.104% |
| I-Tech AB | 27.56 Million SEK | 88.635% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 95.584% |
| Cyxone AB (publ) | 2.61 Million SEK | -19.992% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 7.934% |
| Biosergen AB | -456 Thousand SEK | 787.061% |
| Cantargia AB (publ) | -3.45 Million SEK | 190.785% |
| NextCell Pharma AB | -43.74 Million SEK | 107.161% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 134.077% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 72.072% |
| Nanologica AB (publ) | -76 Thousand SEK | 4222.368% |
| SynAct Pharma AB | -778 Thousand SEK | 502.699% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 1723.316% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 124.245% |
| Lipum AB (publ) | 53 Thousand SEK | -5811.321% |
| BioInvent International AB (publ) | 71.46 Million SEK | 95.616% |
| Alzinova AB (publ) | 19.87 Million SEK | 84.236% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 91.369% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -114.146% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 20986.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -88.963% |
| Simris Alg AB (publ) | 2 Million SEK | -56.104% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 187.514% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 91.147% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 398.665% |